Erlotinib-induced acute hepatitis in a patient with pancreatic cancer.
Saif
Muhammad Wasif
MW
Medical Oncology and Developmental Therapeutics Program, Yale University School of Medicine, New Haven, CT 06510, USA. wasif.saif@yale.edu
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000201:enzymology; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology*; D003577:Cytochrome P-450 Enzyme System / Q000187:drug effects; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D000069347:Erlotinib Hydrochloride; D006801:Humans; D008099:Liver / Q000201:enzymology; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000201:enzymology; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D011799:Quinazolines / Q000009:adverse effects*; D000093542:Gemcitabine
D000964:Antimetabolites, Antineoplastic; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D003841:Deoxycytidine; D003577:Cytochrome P-450 Enzyme System; D000069347:Erlotinib Hydrochloride; D066246:ErbB Receptors; D000093542:Gemcitabine